On June 5, 2024, Eli Lilly and Company announced that Anat Ashkenazi resigned as chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry. Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company. During his 29-year career with the Company, Mr. Brooks has held various leadership roles across the Company?s finance organization, including as senior vice president, chief procurement officer, from February 2019 to March 2024, prior to becoming the group vice president, controller and corporate strategy.

Previous finance leadership roles held by Mr. Brooks include chief financial officer for Lilly U.S. Bio-Medicines, chief financial officer of manufacturing and quality, leader of the Company?s corporate finance investment banking group, and general auditor. Ms. Ashkenazi will remain at the Company through the end of July 2024 to facilitate the transition of her responsibilities.